Recombinant Human NRG1 isoform 9/GGF-2 Protein, CF

Measured in a serum-free cell proliferation assay using MCF-7 human breast cancer cells. The ED50 for this effect is 0.750-7.50 ng/mL.

2 μg/lane of Recombinant Human NRG1 isoform 9/GGF-2 Protein (Catalog # 11505-NR) was resolved with SDS-PAGE under reducing (R) and non-reducing (NR) conditions and visualized by Coomassie® Blue staining, showing bands at 70‑80 kDa, under reducing conditions.

• Reactivity: Hu
• Applications: Bioactivity
• Format: Carrier-Free

Recombinant Human NRG1 isoform 9/GGF-2 Protein, CF Summary

• Details of Functionality: Measured in a serum-free cell proliferation assay using MCF‑7 human breast cancer cells. Karey, K.P. et al. (1988) Cancer Research 48:4083. The ED₅₀ for this effect is 0.750-7.50 ng/mL.
• Source: Chinese Hamster Ovary cell line, CHO-derived human Neuregulin-1/NRG1 protein
  (isoform 9/GGF-2) Gly51-Glu422
  Accession # Q02297-9
• Accession #: Q02297-9
• N-terminal Sequence: Gly51
• Protein/Peptide Type: Recombinant Proteins
• Purity: >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
• Endotoxin Note: <0.10 EU per 1 μg of the protein by the LAL method.

Applications/Dilutions

• Dilutions:
  • Bioactivity
• Theoretical MW: 40 kDa.
  Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
• SDS-PAGE: 70-80 kDa, under reducing conditions.

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose.
• Purity: >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
• Reconstitution Instructions: Reconstitute at 500 μg/mL in PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Recombinant Human NRG1 isoform 9/GGF-2 Protein, CF

• ARIA
• GGF2
• GGFglial growth factor
• Heregulin-1
• HGL
• HGLneu differentiation factor
• HRG
• HRG1
• HRG1-alpha
• HRG1-beta 1
• HRGAneuregulin 1 type IV beta 1a
• MST131
• MSTP131
• NDFheregulin, alpha (45kD, ERBB2 p185-activator)
• neuregulin 1 type IV beta 3
• neuregulin 1
• Neuregulin1
• Neuregulin-1
• NRG1
• pro-neuregulin-1, membrane-bound isoform
• pro-NRG1
• sensory and motor neuron derived factor
• SMDF

Background

Glial growth factor2, GGF-2, also known as cimaglermin alfa or NRG1 beta 3 (1), is a full-length splice variant of the Neuregulin-1 (NRG1) family gene. NRG1 is one of the four members  of the neuregulin family of genes (NRG1-4) encoding signaling proteins that facilitate cell–cell interactions in many tissues, including the nervous system and the heart (2). All family members share an EGF-like domain that interacts with the ErbB family of tyrosine kinase receptors. Through their displayed interaction with ERBB receptors, NRG1 isoforms induce the growth and differentiation of epithelial, neuronal, glial, and other types of cells. The ErbB2 and ErbB4 receptors cooperate in transmission of neuregulin-1 signals in the heart, whereas ErbB2 and ErbB3 cooperate in neural crest cells.Neuregulins are emerging as potential treatments for heart failure. GGF-2 was chosen as a development candidate with potentially long-lasting pharmacodynamic activity (4).

1. Dimayuga, F.O. et al. (2003) J Neuroimmunol 136:67.
2. Falls D.L. (2003). Exp. Cell Res. 284:14.
3. Marchionni M.A. et al. (1999) Adv Exp Med Biol. 468:283.
4. Caggiano A.O. et al. (2017) Eur J Pharmacol.796:76.

Bioinformatics

• Uniprot:
  • Q02297-9()